GlassScriptPhysician profile
William Whitney Robertson
NPI 1740404904
$4,392.61
in general payments reported to CMS, 2019-2025
40 companies · $501 in 2025
The $501 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $508 · 2021: $538 · 2022: $368 · 2023: $523 · 2024: $524 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.79 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $605.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $476.16 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Abbvie INC. | $428.84 | 2019-2025 | Venclexta |
| Pfizer INC. | $264.70 | 2019-2023 | |
| Celgene Corporation | $224.07 | 2019-2025 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $205.33 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $191.71 | 2019-2020 | |
| Seagen INC. | $156.68 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $153.76 | 2021-2023 | Imbruvica |
| Eisai INC. | $128.79 | 2019-2025 | |
| Amgen INC. | $127.49 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Daiichi Sankyo INC. | $123.03 | 2019-2025 | Enhertu, Injectafer |
| Astellas Pharma US INC | $118.42 | 2019-2025 | Padcev, Xospata, Vyloy |
| Merck Sharp & Dohme LLC | $112.51 | 2019-2020 | |
| Janssen Biotech, INC. | $107.24 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.